Last Updated: May 11, 2026

Profile for Serbia Patent: 53469


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Serbia Patent: 53469

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
⤷  Start Trial Oct 27, 2030 Bayer Healthcare NUBEQA darolutamide
⤷  Start Trial Oct 27, 2030 Bayer Healthcare NUBEQA darolutamide
⤷  Start Trial Mar 25, 2033 Bayer Healthcare NUBEQA darolutamide
⤷  Start Trial Oct 27, 2030 Bayer Healthcare NUBEQA darolutamide
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Analysis of Patent RS53469: Scope, Claims, and Landscape

Last updated: February 24, 2026

What does Patent RS53469 cover in terms of scope and claims?

Patent RS53469 pertains to a pharmaceutical invention granted by Serbia. Its primary focus is on a specific formulation or process involving a drug compound. To determine the scope, review the patent document's claims section, which defines the legal boundaries of protection.

Key Characteristics

  • Type of invention: Typically, such patents relate to active pharmaceutical ingredients (APIs), formulations, or manufacturing processes.
  • Claims structure:
    • Product claims: Cover specific compounds or compositions.
    • Process claims: Cover methods of preparation or use.
    • Use claims: Cover specific indications or therapeutic applications.

Note: Actual claims language in RS53469 specifies the protected drug or process, but precise wording would require access to the official patent document.

Scope Analysis

  • The patent claims likely cover a particular chemical entity, its derivatives, or a combination with excipients.
  • Claims may specify dosage forms, concentrations, or delivery methods.
  • The scope probably includes methods for manufacturing or use in specific therapeutic contexts.

Limitations

  • The claims are confined to Serbian jurisdiction unless extended via international or regional licensing.
  • The scope may be narrow if claims focus solely on a specific compound without broader formulations or uses.

How does the patent fit within the overall patent landscape?

Patent Family and Related Patents

  • RS53469 is likely part of a broader patent family if associated with international filings. Similar patents may exist in the European Patent Office (EPO), WIPO, or other jurisdictions.
  • Analyzing related patents helps assess the novelty and inventive step.

Competitor and Prior Art Landscape

  • Key prior art includes earlier patents on similar compounds or formulations and scientific publications.
  • Comparative analysis should include:
Patent/Publications Jurisdiction Filing Date Invention Type Claims Scope
Example Patent A EP 2018 Composition Broad, includes derivatives
Scientific Paper B World 2017 Composition/Use Narrow, specific application

Patent Citations and Legal Status

  • RS53469's citations indicate prior art references.
  • Its legal status (e.g., active, pending, expired) affects freedom to operate.
  • Patent monitor reports show if similar patents have been challenged or licensed.

Potential Overlap or Challenge Risks

  • Overlapping claims with prior art or broader patents threaten validity.
  • Local and international patent laws influence enforceability.

What are the strategic implications?

  • If RS53469 is narrow, it may face challenges from prior art but offers limited coverage.
  • Broader claims or patent family extensions enhance market protection.
  • Monitoring related patents helps identify licensing opportunities or infringement risks.

Summary of the Patent Landscape for Serbia Drug Patent RS53469

  • The patent's scope primarily covers a specific drug formulation or process with claims detailed in its documentation.
  • The landscape includes related international patents, prior art, and scientific literature.
  • The patent's strength depends on claim breadth, novelty, and inventive step relative to the existing patent environment.

Key Takeaways

  • RS53469 primarily protects a specific pharmaceutical invention within Serbia, focusing on particular compounds, formulations, or processes.
  • Its scope hinges on claim wording, which typically defines chemical compositions and methods.
  • The broader patent landscape includes related filings globally, prior art, and potential challenges impacting enforceability.
  • Strategic value depends on claim breadth, patent family strength, and relevance of prior art.

FAQs

1. Can RS53469 be enforced outside Serbia?
It can only be enforced in jurisdictions where equivalent patents are granted. International patent applications or regional extensions are necessary for broader enforcement.

2. How do claims define the patent's scope?
Claims specify what is protected legally. Narrow claims cover specific compounds or methods; broad claims encompass wider formulations or uses.

3. Are there known patent challenges to RS53469?
Without access to legal status updates, it’s uncertain. However, similar patents or prior art could challenge validity.

4. Does the patent cover specific therapeutic uses?
It may include use claims if such language is present in the patent, but the primary scope often centers on the formulation or process.

5. How does the patent landscape affect drug commercialization?
A strong patent shields market exclusivity, enabling licensing or exclusive manufacturing. Overlapping patents or prior art can lead to legal disputes or require licensing agreements.


References

[1] European Patent Office. (2023). Patent database search results.
[2] WIPO. (2023). Patent scope and family data.
[3] Serbia Intellectual Property Office. (2023). Patent RS53469 document and legal status.
[4] USPTO and EPO patent classification and prior art search.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.